Nuvectis Pharma, Inc. NVCT 深 滬
已收盤 04-02 16:00:00 美东时间
7.56
-0.040
-0.53%
華盛通- 最 高7.5674
- 今 開7.44
- 成交量 1.83万股
- 最 低 7.44
- 昨 收 7.60
- 總市值 2.00亿
- 52周最高 11.52
- 市盈率 靜 --
- 換手率 0.07%
- 52周最低 5.55
- 委 比 10.45%
- 總股本 2649.17万
- 歷史最高 20.92
- 量 比 0.33
- 振 幅 1.68%
- 歷史最低 3.08
- 每 手 1
- 風險率 1.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
<p>Nuvectis Pharma, Inc. announced that it will present three abstracts for NXP900, a Phase 1b, first-in-class YES1/SRC inhibitor, at the 2026 AACR Annual Meeting in San Diego. The presentations will focus on NXP900's synergistic effects with KRAS inhibitors in NSCLC models, overcoming resistance to SFK inhibitors in cholangiocarcinoma, and targeting MDSCs in NSCLC via SRC inhibition. The sessions will take place on April 21st and 22nd, 2026. Nuv...
03-31 12:00
Nuvectis Pharma Q4 EPS $(0.31), Inline
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.31) per share which met the analyst consensus estimate. This is a 13.89 percent increase over losses of $(0.36) per share from the same period last year.
02-11 22:13
Nuvectis Pharma GAAP EPS of -$1.32
Nuvectis Pharma press release (NVCT): FY GAAP EPS of -$1.32. Cash and cash equivalents were $31.6 million as of December 31, 2025, compared to $18.5 million as of December 31, 2024. The increase of $1...
02-11 21:51
Nuvectis Pharma Inc. FY25 net loss attributable to common shareholders widens to USD 28.87 million, up 52%
Nuvectis Pharma Inc. FY25 net loss attributable to common shareholders widens to USD 28.87 million, up 52% Nuvectis Pharma Inc. reported its financial results for the full year ended December 31, 2025. Research and development expenses for the period totaled USD 18.15 million, while general and admi
02-11 20:32
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
FORT LEE, N.J., Feb. 11, 2026 -- Nuvectis Pharma, Inc. reported its 2025 financial results, with cash reserves of $31.6 million and a net loss of $26.4 million. CEO Ron Bentsur highlighted progress in the NXP900 development program, aiming for potential data readouts in 2026, including phase 1b trials. The company remains focused on operational execution and financial responsibility.
02-11 12:30
Nuvectis Pharma Initiated Phase 1b Study Of NXP900 In Combination With Astrazeneca's Tagrisso (Osimertinib) In Patients With EGFRmut+ NSCLC
NXP900 Phase 1b Clinical ProgramThe Phase 1b program was initiated with the NXP900 single agent (monotherapy) study following the successful completion of a Phase 1a dose escalation study in patients with advanced solid
2025-12-17 20:09
BRIEF-Nuvectis Pharma Announces The Initiation Of The Phase 1B Study Of NXP900 In Combination With Osimertinib In Patients With NSCLC
Dec 17 (Reuters) - Nuvectis Pharma Inc NVCT.O: NUVECTIS PHARMA ANNOUNCES THE INITIATION OF THE PHASE 1B STUDY OF NXP900 IN COMBINATION WITH OSIMERTINIB IN PATIENTS WITH NSCLC Source text: ID:nGNE23VgD...
2025-12-17 20:08
Nuvectis Pharma,To Discuss Key NXP900 Preclinical And Clinical Data To Date And Strategy For Monotherapy And Combination Components Of NXP900 Phase 1b Clinical Program At Key Opinion Leader Meeting
Nuvectis Pharma, Inc. (NASDAQ:NVCT, the "Company"))), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need
2025-11-25 21:04
Nuvectis Pharma Q3 EPS $(0.44) Misses $(0.25) Estimate
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.25) by 73.91 percent. This is a 83.33 percent decrease over losses of $(0.24) per share from
2025-11-04 21:30
